[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625576":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":10,"centralContacts":27,"locations":10,"responsibleParty":36,"collaborators":10,"id":38,"slug":10,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":10,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":10},{"fullName":5,"class":6},"LMC Diabetes & Endocrinology Ltd.","OTHER",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"T2D Semaglutide Cohort",null,"Adults with T2D prescribed semaglutide",[13],"Drug: Semaglutide (SEMA)",{"label":15,"type":10,"description":16,"interventionNames":10},"T2D other AHA cohort","Adults with T2D prescribed antihyperglycemic medication beside semaglutide including sulfonylurea, DPP4i, and\u002For SGLT2i",{"label":18,"type":10,"description":19,"interventionNames":20},"Obesity Semaglutide Cohort","Adults with obesity, defined as BMI equal or greater than 27 kg\u002Fm2, prescribed semaglutide",[13],[22],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"DRUG","Semaglutide (SEMA)","participants who initiate semaglutide",[18,9],[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Lisa Chu, PhD","CONTACT","(416) 645-2929","lisa.chu@lmc.ca",{"name":34,"role":30,"phone":31,"phoneExt":10,"email":35},"giovana Romero, Msc","giovana.romero@lmc.ca",{"type":37,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100625576",false,"NCT07424430","Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes","Real-world Canadian Retrospective Study Evaluating Longitudinal SEMAglutide Use on Cardio-Kidney-Metabolic Outcomes","SEMA-CKM","Inclusion Criteria:\n\nT2D Cohort:\n\n* A clinical diagnosis of T2D ≥ 1 year\n* HbA1c ≥ 6.5% (pre-index date)\n* Initiated semaglutide or other AHA(s) before January 1st, 2023\\*\n* Seen by an LMC endocrinologist in the last 18 months as of the query date\n* ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date\n* Informed data consent for their medical record data to be used for research purposes\n\nObesity Cohort:\n\n* 18 years or older\n* BMI ≥ 27 kg\u002Fm2\n* HbA1c \\\u003C 6.5% (pre-index date)\n* Initiated semaglutide before January 1st, 2023\\*\n* Seen by an LMC endocrinologist in the last 18 months as of the query date\n* ≥ one HbA1c value up to 6 months (± 90 days) prior to index date\n* Informed data consent for their medical record data to be used for research purposes\n\nExclusion Criteria:\n\n* Clinical diagnosis of type 1 diabetes\u002Flatent autoimmune diabetes in adults (LADA)\n* Clinical diagnosis of T2D (obesity cohort only)\n* Are pregnant at the time of semaglutide or other AHA initiation or became pregnant during follow-up period\n* Documented history or family history of medullary thyroid carcinoma\n* Participation in a research study with an Investigational Product\n* eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m2 at index date\n* Use of non-semaglutide GLP-1-based medication for more than 6 months after the index date (T2D sema cohort and obesity sema cohort)\n* Use of other AHA for more than 6 months after the index date within the first year of semaglutide use (T2D sema cohort and obesity sema cohort)","ALL","18 Years",{"count":48,"type":49},400,"ESTIMATED","OBSERVATIONAL","The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.",[53,54,55],"Diabetes (DM)","Type 2 Diabetes","Obesity (Disorder)",[57,58,59,60],"semaglutide","T2D","AHA","HbA1c","NOT_YET_RECRUITING","2026-02-13",{"date":64,"type":65},"2026-02-20","ACTUAL",{"date":67,"type":49},"2026-03",{"date":69,"type":49},"2026-05",{"name":5,"class":6}]